中国药品专利强制许可的制度缺陷及改革思路  

The system defects and reform ideas of compulsory licensing of pharmaceutical patents in China

作　　者：王金堂 赵许正 WANG Jin-tang;ZHAO Xu-zheng(Law School,Qingdao University of Science and Technology,Qingdao 266061,China)

机构地区：[1]青岛科技大学法学院,山东青岛266061

出　　处：《青岛科技大学学报（社会科学版）》2021年第4期63-69,共7页Journal of Qingdao University of Science and Technology(Social Sciences)

摘　　要：药品专利强制许可作为一项应对公共卫生危机的非常态制度在国内外得到了立法支持。我国虽然构建了药品专利强制许可制度框架,但至今仍处于"零实施"状态,药品专利强制许可标准的缺失与立法缺陷是造成药品专利强制许可制度未能付诸实践的重要因素。中国药品专利许可制度需要在利益衡量原则的指导下,充分利用TRIPS协议赋予的自主决定权,改革僵化的药品专利强制许可启动机制,在切实保障专利权人合法权益的基础上完善相关立法。As an abnormal system to deal with sudden public health crisis,compulsory licensing of pharmaceutical patents has been supported by legislation at home and abroad.Although China has built the framework of compulsory licensing of pharmaceutical patents,it is still in the state of“zero implementation”.The lack of compulsory licensing of pharmaceutical patent standards and legislative defects are the important factors that cause the system to fail to be put into practice.Under the guidance of the principle of balance of interests,we need to make full use of the independent decision power granted by TRIPS to reform the rigid starting mechanism of compulsory licensing,and improve relevant legislation on the basis of effectively protecting the legitimate rights and interests of the patentees.

关 键 词：药品专利 专利强制许可 药品可及性 TRIPS 

分 类 号：D923.42[政治法律—民商法学]